A new synthetic vaccine developed to deal with chikungunya. The findings, published in the journal – Science Advances Today – yielded exceptionally promising results for the Chikungunya vaccine candidate, engineered using a synthetic protein scaffold that could revolutionize the way vaccines are designed, produced, and stored.
Researchers at the University of Bristol and the French National Center for Scientific Research (CNRS) in Grenoble, France, together with computer tech giant Oracle, have found a way to create a vaccine that designed thermostable (capable of withstanding hot temperatures) can go. Are produced quickly and easily.
“We were working with a protein that makes a polymorphic particle that resembles a virus, but it’s completely safe because there’s no genetic material inside it,” said Pascal Fender, an expert virologist at CNRS . ” Completely coincidentally, we found that this particle was incredibly stable. Even after months, without refrigeration. “
“This particle has a very flexible, exposed surface that can be easily engineered, with the Max Planck-Bristol Center for Minor Biology in Bristol added to Imer Berger.” We felt that we could put small, harmless bits of chikungunya. Virus-like mimics we could potentially use as a vaccine. “
To validate their design, the scientists employed cryo-electron microscopy, a powerful new technique recently established at Bristol’s state-of-the-art microscopy facility, which was co-authored by the study’s co-author Christoph Schafitzel. Cryo-EM gives very large data sets requiring massively parallel computing, the composition of the sample can be determined at near-atomic resolution.
Enabled by Oracle’s high-performance cloud infrastructure, the team developed a novel computational approach to create an accurate digital model of synthetic vaccines.
IT experts Christopher Woods and Matt Williams of the University of Bristol teamed up with Oracle partners to implement software packages originally on the cloud in this pioneering effort.
“We were able to process large data sets obtained by the microscope on a cloud in a fraction of the time and at a much lower cost than previously thought possible,” Christopher explained.
“Researchers have carried on a long tradition of building and installing their own supercomputers, but cloud computing is allowing them to run large data sets in record time, with fast connectivity and low latency,” Phil Bates Added major cloud architect to Oracle.
“It is helping them crunch data and accelerate scientific breakthroughs. Going forward, technologies such as machine learning and cloud computing will play an important role in the scientific world, and we are glad that we can help researchers with this important discovery.
Particles prepared by scientists have yielded exceptionally promising results in animal studies, which set the stage for future vaccines to combat chikungunya disease.
A new synthetic vaccine developed to deal with chikungunya